Insulin resistance is an underlying mechanism of impaired
glucose metabolism during nilotinib therapy

J 2018

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy

RÁČIL, Zdeněk, Eva KORIŤÁKOVÁ, Tomasz SACHA, Hana KLAMOVA, Petra BELOHLAVKOVA et. al.

Základní údaje

Originální název

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy

Autoři

RÁČIL, Zdeněk (203 Česká republika, garant, domácí), Eva KORIŤÁKOVÁ (203 Česká republika, domácí), Tomasz SACHA (616 Polsko), Hana KLAMOVA (203 Česká republika), Petra BELOHLAVKOVA (203 Česká republika), Edgar FABER (203 Česká republika), Delphine REA (250 Francie), Ludmila MALASKOVA (203 Česká republika), Jiřina PROCHÁZKOVÁ (203 Česká republika), Daniela ŽÁČKOVÁ (203 Česká republika, domácí), Jaroslava VOGLOVA (203 Česká republika), Joanna WACLAW (616 Polsko), Petr CETKOVSKY (203 Česká republika), Pavel ZAK (203 Česká republika) a Jiří MAYER (203 Česká republika, domácí)

Vydání

American Journal of Hematology, Hoboken, John Wiley & Sons, 2018, 0361-8609

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 6.137

Kód RIV

RIV/00216224:14110/18:00104917

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1002/ajh.25232

UT WoS

000447533300007

Klíčová slova anglicky

nilotinib therapy

Štítky

14110212, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 5. 2019 14:30, Soňa Böhmová

Anotace

V originále

Impaired glucose metabolism (IGM) with hyperglycemia represents one of the most frequently observed adverse events (AE) during nilotinib therapy of chronic myeloid leukemia (CML). The exact mechanism of IGM remains controversial. Although a case report has shown a decrease in insulin secretion1 , our previous pilot data suggested development of insulin resistance as a possible mechanism.2 In this prospective study we aimed to confirm results from our pilot study using a larger cohort of CML patients treated with nilotinib and to compare results with data obtained on control groups receiving imatinib and dasatinib.

Návaznosti

NV17-30397A, projekt VaV

Název: Mutační analýza primitivních buněčných populací u chronické myeloidní leukémie: za hranicí BCR-ABL1

Citovat

RÁČIL, Zdeněk, Eva KORIŤÁKOVÁ, Tomasz SACHA, Hana KLAMOVA, Petra BELOHLAVKOVA, Edgar FABER, Delphine REA, Ludmila MALASKOVA, Jiřina PROCHÁZKOVÁ, Daniela ŽÁČKOVÁ, Jaroslava VOGLOVA, Joanna WACLAW, Petr CETKOVSKY, Pavel ZAK a Jiří MAYER. Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. American Journal of Hematology. Hoboken: John Wiley & Sons, 2018, roč. 93, č. 10, s. "E342"-"E345", 4 s. ISSN 0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.25232.

@article{1478081,
   author = {Ráčil, Zdeněk and Koriťáková, Eva and Sacha, Tomasz and Klamova, Hana and Belohlavkova, Petra and Faber, Edgar and Rea, Delphine and Malaskova, Ludmila and Procházková, Jiřina and Žáčková, Daniela and Voglova, Jaroslava and Waclaw, Joanna and Cetkovsky, Petr and Zak, Pavel and Mayer, Jiří},
   article_location = {Hoboken},
   article_number = {10},
   doi = {http://dx.doi.org/10.1002/ajh.25232},
   keywords = {nilotinib therapy},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy},
   volume = {93},
   year = {2018}
}

TY  - JOUR
ID  - 1478081
AU  - Ráčil, Zdeněk - Koriťáková, Eva - Sacha, Tomasz - Klamova, Hana - Belohlavkova, Petra - Faber, Edgar - Rea, Delphine - Malaskova, Ludmila - Procházková, Jiřina - Žáčková, Daniela - Voglova, Jaroslava - Waclaw, Joanna - Cetkovsky, Petr - Zak, Pavel - Mayer, Jiří
PY  - 2018
TI  - Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy
JF  - American Journal of Hematology
VL  - 93
IS  - 10
SP  - "E342"-"E345"
EP  - "E342"-"E345"
PB  - John Wiley & Sons
SN  - 03618609
KW  - nilotinib therapy
N2  - Impaired glucose metabolism (IGM) with hyperglycemia represents one of the most frequently observed adverse events (AE) during nilotinib therapy of chronic myeloid leukemia (CML). The exact mechanism of IGM remains controversial. Although a case report has shown a decrease in insulin secretion1 , our previous pilot data suggested development of insulin resistance as a possible mechanism.2 In this prospective study we aimed to confirm results from our pilot study using a larger cohort of CML patients treated with nilotinib and to compare results with data obtained on control groups receiving imatinib and dasatinib.
ER  -

RÁČIL, Zdeněk, Eva KORIŤÁKOVÁ, Tomasz SACHA, Hana KLAMOVA, Petra BELOHLAVKOVA, Edgar FABER, Delphine REA, Ludmila MALASKOVA, Jiřina PROCHÁZKOVÁ, Daniela ŽÁČKOVÁ, Jaroslava VOGLOVA, Joanna WACLAW, Petr CETKOVSKY, Pavel ZAK a Jiří MAYER. Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. \textit{American Journal of Hematology}. Hoboken: John Wiley \&{} Sons, 2018, roč.~93, č.~10, s.~''E342''-''E345'', 4 s. ISSN~0361-8609. Dostupné z: https://dx.doi.org/10.1002/ajh.25232.

Podrobný výpis o publikaci